James H. Cavanaugh
Managing Director @ HealthCare Ventures
James H. Cavanaugh is a Series B investor at HealthCare Ventures focused on Health Care and Biotechnology. James Cavanaugh has been a Managing Director of HealthCare Ventures since 1988. He was previously president of SmithKline & French Laboratories–U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. He had been president of SmithKline Beckman’s clinical laboratory business and president of Allergan International.Earlier Dr. Cavanaugh served in numerous senior posts with the U.S. Government on the White House staff and before that at the U.S. Department of Health and Human Services.Prior to that he was a member of the faculty of the College of Medicine and the Graduate College at the University of Iowa.Dr. Cavanaugh received his Master's and Doctorate degrees from the University of Iowa.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries James H. Cavanaugh invests in
Stages James H. Cavanaugh invests in
Countries James H. Cavanaugh invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Beauty 1 (25%)
- Fashion 1 (25%)
- Medical 1 (25%)
Stage
- Series B 2 (50%)
- Series C 1 (25%)
- Debt Financing 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Colorescience is a luxury aesthetic makeup line in the medical and resort spa channel, differentiating their products from other makeup lines through high quality, efficacious ingredients, luxury colores and formulations, and convenience and simplicity of use. With every product the company strives to make a difference in the diminution of skincancer and skin conditions. | $30M / Debt Financing / Sep 14, 2020 | ||
| Colorescience is a luxury aesthetic makeup line in the medical and resort spa channel, differentiating their products from other makeup lines through high quality, efficacious ingredients, luxury colores and formulations, and convenience and simplicity of use. With every product the company strives to make a difference in the diminution of skincancer and skin conditions. | $15M / Series B / Sep 10, 2014 | ||
| PharmAthene, Inc., a biodefense company, develops medical countermeasures to prevent and treat morbidity and mortality associated with the use of biological and chemical weapons in the United States. Its products, which are under development, include Valortim, a prophylactic and therapeutic anti-anthrax monoclonal antibody; and Protexia, arecombinant form of human butyrylcholinesterase for clinical use in the treatment of organophosphate intoxication due to exposure to chemical nerve agents. The company was founded in 2001 and is headquartered in Annapolis, Maryland. | $50M / Series B / Oct 12, 2004 | ||
Orqis Medical
|
ORQIS Medical Corporation operates as a medical device company. It develops and sells minimally invasive devices for improving cardiac performance through aortic flow therapy. It offers Cancion System, a heart failure treatment that uses continuous aortic flow augmentation technology to improve symptoms of heart failure and change the underlyingcourse of the disease for patients hospitalized for de-compensated heart failure. The company’s products also include Exeleras System to treat chronic heart failure patients. | $25M / Series C / Jun 24, 2003 |
Co-Investors
About HealthCare Ventures
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
HealthCare Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
James H. Cavanaugh
Managing Director
|
|||
|
John Littlechild
Managing Director & General Partner
|
|||
|
Christopher K. Mirabelli
Managing Director
|
|||
Douglas E. Onsi
Managing Director
|
|||
Harold Werner
Co-Founder & Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does James H. Cavanaugh invest in?
James H. Cavanaugh invests primarily in Health Care, Biotechnology and Beauty startups, most often at Series B and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact James H. Cavanaugh?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did James H. Cavanaugh last invest?
The most recent investment recorded for James H. Cavanaugh closed in Sep 2020. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
